Q2 2025 Management View Chairman and CEO Ramon Luis Laguarta explained that PepsiCo is accelerating multi-year productivity initiatives with a specific focus on the North America integration, stating ...

Discover how real-time monitoring and AI improve alloy heat treatment by optimizing phase transformations, reducing waste, and enhancing manufacturing.

East Midlands Councils and Transport for the East Midlands have expressed dismay at the decision to ‘pause’ Midland Main Line ...

Trails Coalition recently awarded a contract to Asbell Construction, of Carl Junction, for the first phase of its plan to connect the Frisco Greenway and the Ruby Jack Trails. That first segment, just ...

"Equinor invests $1.2bn in Johan Sverdrup’s third phase to boost recovery" was originally created and published by Offshore Technology, a GlobalData owned brand.

Aker BP announces that the Johan Sverdrup partnership has made a final investment decision for Phase 3 of the field development. The project includes new subsea infrastructure that will increase ...

--Viatris Inc., a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 in treating presbyopia. Presbyopia is the ...

In interim analysis of phase 2 ASC2ESCALATE trial, patients with chronic-phase chronic myeloid leukemia who fail to respond to first-line therapies show major molecular responses to asciminib.

About Actuate-1801 Part 3B Study The Actuate-1801 Part 3B study (NCT03678883) is a randomized, controlled Phase 2 trial of elraglusib with GnP versus GnP alone in first-line mPDAC.

Already boasting a strong foothold in metastatic triple-negative breast cancer, Gilead Sciences’ Trodelvy has produced positive data that could make the antibody-drug conjugate part of a new ...

We conducted a phase 1a dose-finding trial of exercise therapy as first-line treatment for HR-positive advanced breast cancer (TBCRC 054). Methods: This multicenter trial was conducted using a patient ...

A phase 1b/2 trial of onvansertib in combination with NALIRIFOX for first line treatment of advanced pancreatic cancer (PANCONVA trial).